Thus, breast cancer cells with intrinsic sensitivity to a drug in the PI3K, HDAC inhibitor, DNA damaging platinum, or microtubule inhibitor class, also tend to be sensitive to other agents in that same class. The gene discussed is HDAC9; the disease is breast cancer.